Lisa Ann Kachnic, MD, FASTRO

Radiation Oncology
Accepting New Patients
Virtual Visits/Telehealth
Profile Headshot

Overview

Lisa A. Kachnic, MD, one of the nation’s leading radiation oncologists and a pioneer of new approaches to optimize the effectiveness of radiation therapy, is the Chu H. Chang Professor and Chief of the Department of Radiation Oncology at Columbia University Vagelos College of Physicians and Surgeons (VP&S) and Chief of the Radiation Oncology Service at NewYork-Presbyterian/Columbia University Irving Medical Center (CUIMC). She also serves as Associate Director of Radiation Oncology and Science in the Herbert Irving Comprehensive Cancer Center (HICCC).

Dr. Kachnic’s combined focus on clinical excellence, technological innovation, and patient-centered research continues to advance the field of radiation oncology, which has resulted in over 150 publications and over $17 million in research support from major federal and non-profit agencies. She is widely recognized for gastrointestinal research that has transformed the standard of care for several cancers by integrating novel radiation delivery techniques.

A past president of the American Board of Radiology, Dr. Kachnic is internationally known for her clinical trial leadership positions in the National Cancer Institute and its cooperative group research bases. She currently serves as Vice Chair of the Radiation Oncology Committee and Co-Chair of the Ano-Rectal Subcommittee for the SWOG Cancer Research Network research base, for which she is the multi-modality executive officer, as well as NRG Oncology’s Associate PI of their NCORP (NCI Community Oncology Research Program) and chair of the NCORP’s Cancer Control Committee. At Columbia, she is contact PI of Columbia’s NCORP and is co-PI of several NCI training grants for residents and early career faculty.

Areas of Expertise / Conditions Treated

  • 3D Conformal Radiotherapy
  • Anal Cancer
  • Biliary Tract Cancer
  • Colon Cancer
  • Esophageal Cancer
  • Gastric Cancer
  • Gastrointestinal Cancer
  • Intensity Modulated Radiotherapy (IMRT)
  • Liver Cancer
  • Palliative Radiotherapy
  • Pancreatic Cancer
  • Protons and Stereotactic Body Radiotherapy/Radiosurgery (SBRT)
  • Radiation Therapy
  • Rectal Cancer

Academic Appointments

  • Chu H. Chang Professor of Radiation Oncology

Administrative Titles

  • Chair, Department of Radiation Oncology
  • Associate Director for Cancer Network Strategy in the Herbert Irving Comprehensive Cancer Center

Hospital Affiliations

  • NewYork-Presbyterian / Columbia University Irving Medical Center
  • NewYork-Presbyterian Hudson Valley Hospital

Gender

  • Female

Schedule an Appointment

Virtual Visits/Telehealth

Virtual Visits allow you to connect with your provider from the comfort, convenience, and safety of your own home.

Schedule Virtual Visit

Phone Appointments

New and Existing Patients:

Connect Patient Portal

For existing patients, login to make an appointment, view documentation or contact your care provider.

Connect Sign In

Location(s)

Insurance Accepted

Aetna

  • Aetna Signature Administrators
  • EPO
  • HMO
  • NY Signature
  • PPO
  • Student Health

Affinity Health Plan

  • Medicaid Managed Care

AgeWell

  • Medicare Managed Care
  • Special Needs

Amerigroup of New Jersey

  • New Jersey Services (Medicaid Managed Care)

Cigna

  • EPO
  • Great West (National)
  • HMO
  • Medicare Managed Care
  • POS
  • PPO

Emblem/GHI

  • Medicare Managed Care
  • PPO

Emblem/HIP

  • ConnectiCare
  • EPO
  • Essential Plan
  • HMO
  • Medicare Managed Care
  • POS
  • PPO
  • Select Care (Exchange)
  • Vytra

Empire Blue Cross Blue Shield HealthPlus

  • Child/Family Health Plus
  • Essential Plan
  • Medicaid Managed Care

Fidelis Care

  • Child/Family Health Plus
  • Essential Plan
  • Medicaid Managed Care
  • Medicare Managed Care

Healthfirst

  • Child/Family Health Plus
  • Leaf (Exchange)
  • Medicare Managed Care

Local 1199

  • Local 1199
  • NYP Employee Plan

MagnaCare (National)

  • MagnaCare

Medicare

  • Railroad
  • Traditional Medicare

Multiplan

  • Multiplan

MVP Health Care

  • Child/Family Health Plus
  • Essential Plan
  • HMO
  • Medicaid Managed Care

Quality Health Management

  • Quality Health Management

RiverSpring

  • Special Needs

UnitedHealthcare

  • Compass (Exchange)
  • Empire Plan
  • HMO
  • Medicaid (Community Plan)
  • Oxford Freedom
  • Oxford HMO
  • Oxford Liberty
  • POS
  • PPO

VNSNY CHOICE

  • Medicare Managed Care
  • SelectHealth
  • Special Needs

WellCare

  • Medicaid Managed Care
  • Medicare Managed Care
  • New Jersey Services (Medicaid Managed Care)

World Trade Center Health Plan

  • World Trade Center Health Plan

*Please contact the provider’s office directly to verify that your particular insurance is accepted.

Credentials & Experience

Education & Training

  • MD, Tufts University
  • Residency: Harvard University

Committees, Societies, Councils

  • Member, Radiation Therapy Oncology Group (RTOG) Board of Directors
  • Member, NRG Oncology, GI Steering Committee
  • Executive Officer, SWOG
  • Co-chair, SWOG, Anorectal Subcommittee
  • Member, IRCI/NCI/EORTC Metastatic and Relapsed Anal Cancer Taskforce
  • Chair, NRG Oncology, NCI Community Oncology Research Program Cancer Control
  • Member, ASTRO Bone Metastases Treatment Guidelines Committee

Board Certifications

  • Radiation Oncology

Honors & Awards

  • 2021- Present: New York Times Magazine “New York Super Doctors”
  • 2020- Present: New York Magazine “Best Doctors in New York
  • 2018: Nashville Magazine, “Best Doctors in Nashville”
  • 2015- Present: U.S. News & World Report “Best Doctors”
  • 2009: American Cancer Society Excellence in Clinical Cancer Care Award
  • 2008: TPG “Next Generation Investigator” Award
  • 2007-2015: Boston Magazine, “Best Doctors in Boston”
America's Top Doctor
NY Top Doctor

Research

Dr. Kachnic is nationally and internationally recognized for her gastrointestinal (GI), patient outcomes and health disparities cancer research and has served as the lead PI for Columbia’s NCORP, which brings cancer clinical trials to affiliated hospital sites serving minority or underserved patient populations. She has extensive experience leading phase II- III clinical trials that have changed the standard of radiation care.

Her research specialty in gastrointestinal cancers has focused on evaluating novel radiochemotherapy combinations as well as technological-advanced radiotherapy delivery strategies to improve cancer outcomes and quality of life post-recovery.

Research Interests: Cancer Care Delivery, Gastrointestinal (GI) and Cancer Control and Prevention Research

Selected Publications

  1. Horowitz DP, Goodman K,Kachnic LA.(2021).Ablative Radiotherapy for Patients With Inoperable Pancreas Cancer-Ready for Prime Time?JAMA Oncol. 7(5):687-688. PMID: 3370435
  2. Kachnic LA, Winter KA, Myerson RJ, Goodyear MD, Abitbol AA, Streeter OE, Augspurger ME,Schefter TE, Katz AW, Fisher BJ, Henke LE, Narayan S, Crane CH.(2022).Long-Term Outcomes ofNRG Oncology/RTOG 0529: A Phase 2 Evaluation of Dose-Painted Intensity Modulated RadiationTherapy in Combination With 5-Fluorouracil and Mitomycin-C for the Reduction of Acute Morbidity in Anal Canal Cancer.Int J Radiat Oncol Biol Phys. 112(1):146-157. PMCID: PMC868829
  3. Pisansky TM, Pugh SL, Greenberg RE, Pervez N, Reed DR, Rosenthal SA, Mowat RB, Raben A,Buyyounouski MK,Kachnic LA, Bruner DW. (2014).Tadalafil for Prevention of Erectile Dysfunctionafter Radiotherapy for Prostate Cancer: The Radiation Therapy Oncology Group [0831] Randomized Clinical Trial.JAMA.311(13): 1300-7.PMCID: PMC466905
  4. Kachnic LA, Winter KA, Myerson RJ, Goodyear MD, Abitbol AA, Streeter OE, Augspurger ME,Schefter TE, Katz AW, Fisher BJ, Henke LE, Narayan S, Crane CH.(2022).Long-Term Outcomes of NRG Oncology/RTOG 0529: A Phase 2 Evaluation of Dose-Painted Intensity Modulated Radiation Therapy in Combination With 5-Fluorouracil and Mitomycin-C for the Reduction of Acute Morbidity inAnal Canal Cancer.Int J Radiat Oncol Biol Phys. 112(1):146-157. PMCID: PMC8688291
  5. Barton DL, Pugh SL, Ganz PA, Plaxe SC, Koontz BF, Carter J, Greyz-Yusupov N, Page SJ, RowlandKM Jr, Balcueva EP, Nabeel S, Basil JB, Hill ML, Muller CY, Bell MC, Deshmukh S, Kachnic LA.(2022).Randomized Controlled Phase II Evaluation of Two Dose Levels of Bupropion Versus Placebo for Sexual Desire in Female Cancer Survivors: NRG-CC004.J Clin Oncol. 40(4):324-334. PMCID:PMC8797544

    For a complete list of publications, please visit PubMed.gov